- Dec 16, 2024 Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
- Nov 12, 2024 Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
- Nov 04, 2024 Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
- Oct 10, 2024 Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
- Oct 01, 2024 Foghorn Therapeutics to Participate in the BMO Oncology Summit
- Sep 03, 2024 Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
- Aug 28, 2024 Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
- Aug 08, 2024 Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
- May 28, 2024 Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
- May 22, 2024 Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
Displaying 1 - 10 of 92